33 results about "Cutaneous wound" patented technology

The present invention relates to a monolithic biomaterial. The monolithic biomaterial has a primary network of convective flow, microfluidic channels that are embedded in a substrate, where the substrate is diffusively permeable to aqueous solutes. The present invention also relates to a method of making the monolithic biomaterial, as well as methods of using the monolithic biomaterial to facilitate healing of a cutaneous wound of a mammalian subject and of regulating cells.

A topical composition for treating a cutaneous wound includes whole colostrum or one or more growth factors, as well as a base by which the whole colostrum or one or more growth factors are carried. The topical composition may also include, without limitation, immunomodulators, lactoferrin, enzymes, vitamins, minerals, amino acids, or combinations thereof. Other components may also be included in the topical composition, including, but not limited to, antiseptics, antimicrobial agents, and anesthetics. When applied to a wound, the bioactive topical composition promotes healing of the treated wound.

A method for restructuring a biological tissue comprising collagen fibrils selected from a venous tissue, a cardiac valvular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia or a tissue of a muscular aponeurosis, comprising the following operational steps: a) bringing into contact a biological tissue comprising collagen fibrils with a cross-linking chemical composition able to induce cross-linking of collagen fibrils consequent to activation through electromagnetic radiation; b) activating said cross linking chemical composition through exposure to an electromagnetic radiation; c) cross-linking the collagen fibrils of said biological tissue in order to obtain a restructured biological tissue. The method according to the invention can be applied to recover a venous continence and both a venous and a cardiac valve diameter. The method reduces the visibility of cutaneous wrinkles, reinforces or repairs tendons, muscular fascia and aponeurosis as well as to heals surgical or traumatic cutaneous wounds or cutaneous ulcers.

The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2/Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.

Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a CIRP inhibitor.

The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.

Compositions and methods are provided for enhanced healing of wounds, e.g. cutaneous wounds, by application of a scaffold or matrix, e.g. a hydrogel film comprising a dose of macrophages, or monocyte progenitors thereof, which dose is effective in increasing the rate of wound healing. The compositions of the invention find use in treating cutaneous wounds, particularly chronic wounds, e.g. in diabetic patients or other patients with impaired wound healing.

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate,—pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.

Cutaneous ulcers and non-healing skin wounds are a route for infection and represent a source of significant morbidity and mortality for humans. The present disclosure provides methods and compositions for treating, healing or preventing cutaneous ulcers and non-healing cutaneous wounds via the topical application of an effective amount of a nitric oxide (NO)-donating prostaglandin F2-alpha (PGF2-alpha) analog directly to the affected ulcer or non-healing cutaneous wound of a human in need of such treatment

The present invention provides compositions and methods to enhance cutaneous wound healing in subjects afflicted with, or at risk for, a pulmonary infection and/or a pulmonary injury. More specifically, the embodiments of the present invention relate to using fibrin carrier as a vehicle to topically deliver one or more chemokine onto a cutaneous wound so as to accelerate wound healing.

The present invention concerns the use of cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue to promote the regeneration of tissue following lesions caused by irradiation. More specifically, the use according to the invention aims to prepare a drug for promoting regeneration of the skin, and in particular to repair the cutaneous wounds caused by irradiation.

A contactless wound treatment barrier assembly carrying a primed wound treatment composition carrier is secured to a patient's skin at a location encapsulating a wound. A wound treatment composition is emitted from the carrier in a gaseous state. The gaseous emission remains within an interior volume of the wound treatment barrier assembly. The design of the wound treatment barrier assembly can minimize any contact between a body of the wound treatment barrier assembly, the wound treatment composition carrier and the wound. An insole carrying a wound treatment composition (such as elemental Iodine) can be used in any of a variety of forms. The insole would deliver the treatment composition. The insole can be designed to provide contactless or contact delivery of the treatment composition.